Tumor microenvironment parameters as a predictor of the duration of clinical effectiveness of immunotargeted therapy in advanced or metastatic endometrial cancer: A pilot multicenter observational study

Tumor microenvironment parameters as a predictor of the duration of clinical effectiveness of immunotargeted therapy in advanced or metastatic endometrial cancer: A pilot multicenter observational study

Background. The inclusion of lenvatinib in the immunotherapy regimen for patients with MSS/pMMR endometrial cancer (EC) is due to its ability to modulate the tumor microenvironment, which allows the use of pembrolizumab in low-immunogenic tumors. However, only 30 % of patients with advanced or metas...

Full description

Saved in:
Bibliographic Details
Main Authors: A. A. Maltseva, A. Yu. Kalinchuk, N. V. Krakhmal, N. M. Chernorubashkina, E. S. Martynova, R. A. Zukov, A. A. Gofman, A. B. Villert, O. N. Churuksaeva, L. A. Kolomiets, L. A. Tashireva
Format: Article
Language:Russian
Published: ABV-press 2024-05-01
Series:Опухоли женской репродуктивной системы
Subjects:
endometrial cancer
immunotargeted therapy
predictors of response
progression-free survival
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/1213
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items